文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

内毒素活性检测在脓毒症中的临床应用:范围综述

Clinical applications for the endotoxin activity assay in sepsis: a scoping review.
PubMed 文献 · Crit Care · 2026-01-30
一句话结论范围综述显示内毒素活性检测(EAA)在脓毒症中最多用于血液净化治疗的入选标准,EAA≥0.6为三项RCT采用的入选阈值之一。

该范围综述检索Embase、Web of Science、MEDLINE和Cochrane Library(建库至2025年5月),纳入95篇在人类患者中应用EAA的研究,其中54篇聚焦脓毒症,发表于2002至2025年,涵盖成人及儿科患者。研究主要来自欧洲(51.9%)、亚洲(22.2%)和北美(11.1%)。最常见场景是将EAA作为脓毒症血液净化治疗(主要为多黏菌素B血液吸附)的入选标准;54篇中3项RCT(北美、泰国、瑞士)以EAA≥0.6作为脓毒症休克入选标准之一,研究内毒素吸附治疗及带吸附滤器的连续性肾脏替代治疗。48.1%的研究对每例患者测量EAA超过两次,提示系列内毒素监测具有临床关注度。作者认为EAA有潜力成为ICU精准医学的组成部分,但需进一步验证研究以确定脓毒症患者的相关时机、频率和截断值。

要点

  • 54篇脓毒症相关研究中,最常见应用场景是将EAA作为血液净化治疗(主要为多黏菌素B血液吸附)的入选标准。
  • 3项RCT(北美、泰国、瑞士)在脓毒症休克中采用EAA≥0.6作为入选标准之一,研究内毒素吸附治疗及带吸附滤器的连续性肾脏替代治疗。
  • 48.1%的研究对每例患者测量EAA超过两次,提示系列内毒素监测受到临床关注。
  • 研究发表于2002至2025年,覆盖成人及儿科患者,主要来自欧洲(51.9%)、亚洲(22.2%)和北美(11.1%)。
  • 作者认为EAA有潜力成为ICU精准医学的组成部分,用于识别最可能从血液净化等靶向干预中获益的患者亚组,但需进一步验证研究确定时机、频率和截断值。

适用人群与场景

  • 成人及儿科脓毒症患者,研究场景为EAA测量用于脓毒症管理。
  • 排除综述、社论、会议摘要、灰色文献及非人类研究。

诊断标准与关键阈值

  • 三项RCT以EAA≥0.6作为脓毒症休克患者血液净化治疗的入选标准之一。

研究设计与关键结果

  • 范围综述检索Embase、Web of Science、MEDLINE和Cochrane Library(建库至2025年5月),最终纳入95篇在人类患者中应用EAA的研究,其中54篇聚焦脓毒症。
  • 54篇脓毒症研究发表于2002至2025年,报告成人及儿科患者的EAA结果,主要来自欧洲(51.9%)、亚洲(22.2%)和北美(11.1%)。
  • 最常见研究场景为将EAA作为脓毒症血液净化治疗(主要为多黏菌素B血液吸附)的入选标准。
  • 54篇中3项为RCT,分别在北美、泰国和瑞士开展,研究内毒素吸附治疗及带吸附滤器的连续性肾脏替代治疗对脓毒症休克的效应,均以EAA≥0.6作为入选标准之一。
  • 48.1%的研究对每例患者测量EAA超过两次,提示系列内毒素监测具有临床关注度。

证据类型、等级与局限

  • 证据类型:范围综述(scoping review),系统检索四个数据库,排除综述、社论、会议摘要、灰色文献及非人类研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为EAA有潜力成为ICU精准医学的组成部分,通过识别最可能从血液净化等靶向干预中获益的患者亚组发挥作用。
  • 作者指出需结合其他生物标志物并开展进一步验证研究,以确定脓毒症患者EAA测量的相关时机、频率和截断值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The Endotoxin Activity Assay™ (EAA) is a commercially available diagnostic test that quantifies endotoxin activity in human whole blood. Despite its promising features, the clinical utility of the EAA in the management of sepsis remains incompletely understood. This study aims to comprehensively review the published literature on the EAA and explore its usage trends and clinical applications in sepsis management. METHODS: We conducted a scoping review focused on EAA measurement in human sepsis subjects across four major databases: Embase, Web of Science, MEDLINE, and Cochrane Library. All the studies published from the inception of the databases to the search date in May 2025 were screened. Reviews, editorials, conference abstracts, grey literature, and non-human studies were excluded. We extracted and analyzed cohort characteristics, timing and frequency of EAA measurement, and the reported EAA results. RESULTS: Our systematic search and screening identified 95 articles that applied EAA on human patients, 54 of which focused on sepsis. These studies were published between 2002 and 2025 and reported EAA results in adult and pediatric patients. Most studies were conducted in Europe (51.9%), Asia (22.2%), and North America (11.1%). The most common study scenario involved using EAA as an inclusion criterion for blood purification therapy for sepsis, primarily polymyxin-B hemoadsorption. Of the 54 studies, three were randomized controlled trials conducted in North America, Thailand, and Switzerland. These trials investigated the effect of endotoxin adsorption therapy and continuous renal replacement therapy with adsorption filters for septic shock, using EAA ≥ 0.6 as part of the inclusion criteria. Nearly half of the studies (48.1%) measured EAA levels more than twice per patient, suggesting that serial endotoxin monitoring is of clinical interest. CONCLUSIONS: Our results highlight the clinical application of EAA measurement in sepsis patient populations worldwide, particularly its potential role in the application of blood purification therapy. Together with other biomarkers and further validation studies to establish relevant timing, frequency, and cut-off values for sepsis patients, the EAA has the potential to become a component of precision medicine in the ICU by identifying patient subgroups most likely to benefit from targeted interventions, such as blood purification.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Komaru Y, Maeda A, Inokuchi R, et al. Clinical applications for the endotoxin activity assay in sepsis: a scoping review. Crit Care. 2026. PMID: 41618465. doi:10.1186/s13054-026-05868-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。